Table 2.
Patient and disease characteristics by induction strategy utilized
| Variable | bortezomib-based | IMID-based | combination |
|---|---|---|---|
| Patient characteristics: | |||
| Age (mean, SD) | 52 (+/−9) | 56 (+/−7) | 57 (+/−9) |
| Gender (% female) | 28 | 50 | 58 |
| KPS (median) | 90 | 90 | 90 |
| Induction length: | |||
| - cycles (median, range) | 4 (2–7) | 4 (3–6) | 3 (2–4) |
| - months (median, range) | 5 (4–11) | 5 (3–12) | 5 (3–10) |
| Response to induction (%): | |||
| - CR | 8 | 0 | 0 |
| - PR | 84 | 88 | 94 |
| - less than PR | 8 | 12 | 6 |
| Disease characteristics: | |||
| Durie-Salmon stage (median) | 3 | 3 | 3 |
| High-risk cytogenetics present (%) | 40 | 44 | 70 |
| M-protein (mean, range, g/dl) | 2.9 (0.4–4.2) | 2.7 (0.2–5.3) | 2 (0.2–5.2) |
| Involved FLC (mean, range, mg/l) | 748 (9–3850) | 224 (12–1150) | 590 (23–4910) |
| Bone marrow plasmacytosis | |||
| - aspirate (mean, SD, %): | 33 (19) | 30 (17) | 28 (13) |
| - core biopsy (mean, SD, %): | 49 (24) | 52 (27) | 46 (27) |